Skip to main content
Suven Life Sciences Ltd. logo

Suven Life Sciences Ltd. — Investor Relations & Filings

Ticker · SUVEN ISIN · INE495B01038 LEI · 3358001IFOGM16J8ZA04 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 746 across all filing types
Latest filing 2026-05-14 Earnings Release
Country IN India
Listing BSE.NS SUVEN

About Suven Life Sciences Ltd.

https://www.suven.com/

Suven Life Sciences Ltd. focuses on the discovery and development of novel therapeutic agents for Central Nervous System (CNS) disorders. The company specializes in New Chemical Entity (NCE) research, targeting unmet medical needs in conditions such as Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s disease, and depression. Its clinical pipeline includes lead candidates like Masupirdine (SUVN-502) for cognitive impairment and Samelisant (SUVN-G3031) for narcolepsy. Suven utilizes an integrated drug discovery platform and maintains a significant global intellectual property portfolio. The organization provides drug discovery and development support services, leveraging expertise in medicinal chemistry and pharmacology to advance internal programs and collaborative research initiatives.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Earnings Release Classification · 78% confidence The document is a newspaper advertisement filed with the stock exchanges under SEBI LODR Regulation 33 containing the company’s audited standalone and consolidated financial results for the quarter and year ended 31 March 2026. It provides key financial metrics (total income, net profit, EPS, etc.) in summary tabular form as an initial public disclosure of periodic results. This aligns with an Earnings Release rather than a full Annual Report or Interim Report. Therefore, it is classified as an Earnings Release. FY 2026
2026-05-14 English
Monitoring Agency Report
Capital/Financing Update Classification · 85% confidence The document is a Monitoring Agency Report filed under SEBI ICDR and LODR regulations, containing detailed tables on the utilization and deployment of proceeds from a preferential equity issue. It is not an AGM, call transcript, earnings release, interim financial report, or management change notice. It represents a compliance update on the company’s capital‐raising transaction (monitoring of preferential issue proceeds), fitting the “Capital/Financing Update” category.
2026-05-14 English
Newspaper Publication - Financial Results
Earnings Release Classification · 87% confidence The document is a statutory newspaper advertisement of audited standalone and consolidated results for the quarter and year ended March 31, 2026, filed with stock exchanges under SEBI (LODR) Regulation 33. It contains summary financial results (income, profit, equity, EPS) rather than a full annual report or bound interim report with notes and analysis. This type of initial release of periodic financial results aligns with the “Earnings Release” category. FY 2026
2026-05-14 English
Monitoring Agency Report for the quarter ended March 31, 2026
Capital/Financing Update Classification · 95% confidence The document is a SEBI-mandated Monitoring Agency Report detailing the quarter‐end utilization and deployment of proceeds from a Preferential Issue (a capital‐raising transaction). It contains substantive financial tables showing funding usage and unutilized cash, fulfilling a compliance requirement on capital/financing. This is not a full interim or annual report, nor a simple announcement—rather it is the actual monitoring report on fundraising proceeds. It therefore falls under the “Capital/Financing Update” category (CAP).
2026-05-14 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 80% confidence The document is an official stock‐exchange filing under SEBI LODR Regulation 33 announcing and attaching Audited Standalone and Consolidated Financial Results (including full P&L, balance sheet, cash flows) for the quarter and year ended March 31, 2026. It is not merely a press release or proxy, but the full financial report for the period shorter than a full fiscal year (quarter plus year end results). This aligns with the Interim/Quarterly Report definition. FY 2026
2026-05-13 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 85% confidence The document is a stock exchange filing under SEBI LODR Reg 30 announcing the grant of 133,200 employee stock options under the company’s ESOP scheme. It provides details on the options, vesting schedule, exercise price, etc. This is not a financial report, management change, or earnings release; rather it’s an announcement of a future share issuance arrangement (ESOP grant), i.e., a capital change. Therefore the correct classification is Share Issue/Capital Change (SHA).
2026-05-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.